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Abstract
Aims/hypothesis Health check programmes for chronic dis-
ease have been introduced in a number of countries.
However, there are few trials assessing the benefits and harms
of these screening programmes at the population level. In a
post hoc analysis, we evaluated the effect of population-based
screening for type 2 diabetes and cardiovascular risk factors
on mortality rates and cardiovascular events.
Methods This register-based, non-randomised, controlled trial
included men and women aged 40–69 years without known
diabetes who were registered with a general practice in
Denmark (n = 1,912,392). Between 2001 and 2006, 153,107
individuals registered with 181 practices participating in the
Anglo–Danish–Dutch Study of Intensive Treatment in People
with Screen-Detected Diabetes in Primary Care (ADDITION)-
Denmark study were sent a diabetes risk score questionnaire.
Individuals at moderate-to-high risk were invited to visit their
GP for assessment of diabetes status and cardiovascular risk
(screening group). The 1,759,285 individuals registered with
all other general practices in Denmark constituted the retrospec-
tively constructed no-screening (control) group. Outcomes were
mortality rate and cardiovascular events (cardiovascular disease
death, non-fatal ischaemic heart disease or stroke). The analysis
was performed according to the intention-to-screen principle.
Results Among the screening group, 27,177 (18%) individuals
attended for assessment of diabetes status and cardiovascular
risk. Of these, 1,533 were diagnosed with diabetes. During a
median follow-up of 9.5 years, there were 11,826 deaths in the
screening group and 141,719 in the no-screening group (HR
0.99 [95% CI 0.96, 1.02], p = 0.66). There were 17,941 car-
diovascular events in the screening group and 208,476 in the
no-screening group (HR 0.99 [0.96, 1.02], p = 0.49).
Conclusions/interpretation A population-based stepwise
screening programme for type 2 diabetes and cardiovascular
risk factors among all middle-aged adults in Denmark was not
associated with a reduction in rate of mortality or cardiovas-
cular events between 2001 and 2012.
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Introduction
As governments seek to apply the principles of prevention
to chronic disease, health check programmes have been
proposed or introduced in a number of countries, including
the UK and the USA [1, 2]. These usually include assess-
ment and management of risk factors for chronic disease,
most of which are related to cardiovascular disease (CVD).
Modelling studies suggest that screening for diabetes and
cardiovascular risk assessment might be both effective and
cost-effective; however, these studies rely on a number of
assumptions [3–7]. There are relatively few trials assessing
the benefits and harms of screening at the population level
[8, 9]. A Cochrane review of randomised trials comparing
health checks with no health checks in adult populations
found that they did not reduce morbidity, all-cause mortal-
ity or cardiovascular-related mortality rates, although the
number of new diagnoses increased [10]. The review in-
cluded data from a number of historical cohorts that were
initiated before the widespread introduction of effective
treatments such as statins. More recent studies examining
the impact of systematic population-wide screening have
shown mixed results. INTER-99 reported no effect and the
Västerbotten Intervention Programme, which combined
screening with a wider public health promotion pro-
gramme, reported mortality rate reductions [9, 11].
Given the limited evidence of the impact of population-
based screening programmes, it is important to explore wheth-
er health checksmight have different impacts in contemporary
populations. It is also critical to evaluate the impact of screen-
ing on overall population mortality rates rather than simply
disease-specific mortality or disease event rates to quantify
overall benefits and harms at the population level [12].
Between 2001 and 2006, a population-based cardiovascular
risk assessment and diabetes screening programme was intro-
duced in five Danish counties as part of the Anglo–Danish–
Dutch Study of Intensive Treatment in People with Screen-
Detected Diabetes in Primary Care (ADDITION) study [13].
The Danish national registration system enables a post hoc
analysis of the rates of mortality and cardiovascular events
in individuals who were invited to take part in the
ADDITION-Denmark screening programme compared with
individuals who were not invited during the same time period.
Methods
ADDITION-Denmark consists of two phases: a pragmatic
screening programme; and a cluster-randomised trial compar-
ing the effects of intensive multifactorial therapy with routine
care among individuals with screen-detected type 2 diabetes
[13, 14]. We report results from a post hoc analysis of data
from the screening phase of the study in conjunction with
outcome data from Danish national registers. Ethical approval
for the ADDITION-Denmark study was granted by a local
scientific committee (no: 20000183). As this was a registry-
based study using anonymised data, participants did not give
informed consent. This approach was approved by the Danish
Data Protection Agency and the Danish Health and Medicine
Authority.
Intervention We performed a population-based stepwise
screening programme among people aged 40–69 years with-
out known diabetes between 2001 and 2006. Full details have
been published previously [13–15]. All general practices in
five out of 16 counties in Denmark (Copenhagen, Aarhus,
Ringkøbing, Ribe and South Jutland) were invited to take part
in ADDITION-Denmark (n = 744); 209 (28.1%) accepted
(county-specific proportions ranged from 21 to 37%).
Eligible individuals aged 40–69 years without diagnosed dia-
betes who were registered with 181 general practices that were
part of the study were sent a diabetes risk score questionnaire
[14, 15]. Individuals who scored ≥5 points (maximum 15
points) were invited to visit their general practitioner (GP)
for a diabetes test and a cardiovascular risk assessment. The
risk score was developed using the Danish Inter99 population
[15]. The sensitivity and specificity for predicting undiag-
nosed diabetes are 68.9–77.0% and 68.8–78%, respectively,
using four different cut-off points [15]. External validation
using the chosen cut-off point of ≥5 was completed using data
from 1028 individuals in a pilot for the ADDITION study and
revealed a sensitivity of 76.0% (95% CI 58.3, 90.3) and spec-
ificity of 72.2% (69.3, 75.1) for diabetes. In Aarhus and
Copenhagen counties, 35 practices also completed opportunis-
tic screening, in which individuals were asked to complete the
risk score questionnaire when attending the practice for other
reasons. Participants who attended a screening appointment
underwent measurement of height, weight, BP, random blood
glucose (RBG), total cholesterol and HbA1c. Participants also
answered a question about their smoking status. GPs were en-
couraged to calculate the European Heart SCORE [16] during
the appointment, to inform individuals about their score and
provide appropriate advice to those at high risk. Individuals
with an RBG ≥5.5 mmol/l or HbA1c ≥ 5.8% (40 mmol/mol)
were invited to return to the practice for a fasting capillary
blood glucose (FBG) test. An OGTT was performed at the
same consultation if FBG was 5.6–6.1 mmol/l and/or
HbA1c ≥ 5.8%. GPs were notified of all results. The WHO
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1999 criteria were used to diagnose diabetes [17], including the
requirement for a confirmatory test on another day.
Participants diagnosed with type 2 diabetes were subse-
quently managed according to the treatment regimen to which
their practice had been allocated: routine care or intensive
treatment [18]. For individuals found to have impaired fasting
glucose (IFG) or impaired glucose tolerance (IGT) [17], and/
or a high CVD risk (SCORE >5 points), practitioners were
encouraged tomanage cardiovascular risk factors according to
national guidelines [19], including annual cardiovascular risk
assessment and diabetes tests.
In order to assess the impact of invitation to screening on
population mortality rates, all individuals in the original
ADDITION-Denmark sampling frame (n = 153,107), includ-
ing those who did not attend for screening, were identified on
the Danish National Registry system (the screening group).
Using the same registry, we also identified all individuals aged
40–69 years without known diabetes who, between 2001 and
2006, were registered with general practices that were not
invited or who declined to take part in ADDITION-
Denmark (n = 1,759,285) (the no-screening group) (Fig. 1).
We linked information about these individuals to other Danish
registers using unique civil registration numbers. We retrieved
information on age, sex, education, region, immigration/emi-
gration, citizenship, redeemed cardioprotective medication
and chronic disease (ischaemic heart disease [IHD], stroke,
cancer). Education was categorised according to UNESCO’s
International Standard Classification of Education [20]. We
grouped data on citizenship into European and non-
European citizens as a proxy for ethnicity.
Outcomes Participants were followed for a median of
9.5 years to 31 December 2012, when national registers were
searched for information on vital status and incident CVD
events. For death, the primary outcome was all-cause mortal-
ity rate (based on underlying cause of death). Secondary out-
comes were cardiovascular-, cancer- and diabetes-relatedmor-
tality rates. Cause-specific deaths were coded blind to study
group using ICD-10 codes (www.who.int/classifications/icd/
en/; electronic supplementary material (ESM) Table 1). For
CVD, the primary outcome was a composite of first event of
cardiovascular death, non-fatal IHD (ICD-10 codes I20–I25
and I46) or non-fatal stroke (ICD-10 code I6*). Data on inci-
dent CVD events was gathered from the National Patient
Registry, which records all inpatient and outpatient
hospitalisations in Denmark.
Statistical analysisAnalysis was by intention-to-screen at the
population level comparing outcomes in people registered at
screening practices with those registered at no-screening prac-
tices. All eligible participants were considered irrespective of
their participation in the screening programme. Baseline char-
acteristics were summarised separately in the screening and
no-screening (control) groups using the unpaired t test for
continuous data and χ2 test for categorical data. Date of entry
to the study for individuals in the screening practices was the
date of invitation to screening. Date of entry for the no-
screening (control) practices was the mid-point (29
June 2003) of the randomisation period of ADDITION-
Denmark practices (2001–2006). Individuals were censored
on the date of first event, date of emigration or 31 December
2012, whichever was earliest. HRs comparing mortality rates
and CVD outcomes between the screening and no-screening
groups were estimated using a Cox proportional hazards re-
gression model. As allocation to screening in ADDITION-
Denmark was at the practice level, robust standard errors were
calculated that take into account the two-level structure of the
data (individuals clustered within practices) [21] and any po-
tential correlation between individuals within practices. We
adjusted for age, sex, education and prevalent chronic disease
(IHD, stroke, cancer). To further account for differences in
social structure, we stratified the baseline hazards by county.
We also compared outcomes between screening attenders with
the no-screening group. Attendance was defined as attending
the initial consultation for diabetes testing and CVD risk as-
sessment. To assess possible bias from unknown antecedent
disease, sensitivity analyses were conducted omitting deaths
from both groups occurring within 1 year of randomisation
(n = 12,375). We also re-ran the Cox model comparing mor-
tality outcomes after excluding individuals affiliated to gener-
al practices undertaking opportunistic screening. We calculat-
ed the proportion of participants who redeemed prescriptions
for lipid-lowering, anti-hypertensive and glucose-lowering
medication from 2000 to 2008 in both groups. All analyses
were completed using Stata version 14.1 (STATA, College
Station, Texas, USA).
Results
The screening and control groups were well balanced for age,
sex and citizenship at baseline (Table 1). Compared with the
control group, a larger proportion of the screening group
(330,096 [19.3%] vs 34,648 [23.1%]) had received >15 years
of education. Slightly higher proportions of the control group
had experienced IHD, stroke or cancer compared with the
screening group.
Of 153,107 eligible people in the screening group, 27,177
(18%) attended their GP for a diabetes test and a cardiovascu-
lar risk assessment. Of these, 1533 participants (1% of those
eligible for screening) were diagnosed with diabetes and 2526
(1.6%) had IFG/IGT. Of all individuals who attended screen-
ing for ADDITION-Denmark with complete data for calculat-
ing CVD risk, 9693/20,223 (48%) had high CVD risk
(European Heart SCORE ≥ 5 points). In total, 6855 (28%)
of attenders with available data reported being a current
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smoker. There were 1,759,285 individuals in the no-screening
control group.
Effect of screening on mortality rate Median duration of
follow-up was 9.5 years (16,954,630 person-years). During
follow-up, there were 11,826 deaths in the screening group
(7.7%) and 141,719 in the no-screening control group
(8.1%) (Table 2). The most common cause of death was can-
cer in the two groups (n = 67,694, 44.5%). Following
adjustment, there was no significant difference in the all-
cause mortality rate between the screening and the control
groups (HR 0.99 [95% CI 0.96, 1.02], p = 0.66) (Table 2).
Sensitivity analyses showed that the overall result was not
affected by the exclusion of people who died within 1 year
of the beginning of the study (n = 12,375; 0.99 [0.96, 1.02],
p = 0.60) or of individuals affiliated to general practices un-
dertaking opportunistic screening (1.00 [0.97, 1.03], p = 0.93).
Compared with the no-screening group, attending for
209 practices agreed to participate 
190 practices randomised to screening and 
routine care or intensive treatment 
19 practices withdrew for 
economic reasons 
9 practices withdrew before screening 
commenced 
744 practices invited to join 
ADDITION-Denmark 
535 practices declined to participate 
27,177 (17.8%) participants attended 
screening 
1533 with screen-detected diabetes 
2526 with IFG/IGT
181 practices included in the 
primary outcome analysis 
153,107 participants 
163,189 aged 40–69 years between 
2001 and 2006 registered at 181
ADDITION-Denmark practices 
Died on or before date of invitation to 
screening, n=655 
Leaving n=162,534 
Not aged 40–69 years on date of 
invitation to screening, n=2250 
Leaving n=160,284 
Had prevalent diabetes 
(n=6805; 4.2%) 
Leaving n=153,479 
Not living in Denmark on date of entry, 
n=372 
Leaving n=153,107
2,343,253 aged 40–69 years between 
2001 and 2006 not registered at an 
ADDITION-Denmark practice 
Died on or before date of entry to the 
study (29 June 2003), n=38,225 
Leaving n=2,305,028 
Not aged 40–69 years on date of entry 
(29 June 2003), n=397,015 
Leaving n=1,908,013 
Had prevalent diabetes 
(n=91,660; 4.8%) 
Leaving n=1,816,353 
Not living in Denmark on date of entry, 
n=23,326 
Leaving n=1,793,027 
No data on GP practice, n=33,742 
Leaving n=1,759,285 
2247 practices included in the primary 
outcome analysis 
1,759,285 participants 
Fig. 1 ADDITION-Denmark
screening flow
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screening was associated with a 25% reduction in risk of death
(0.75 [0.71, 0.78]).
There was no significant difference between groups in car-
diovascular mortality rate (HR 1.02 [95% CI 0.96, 1.08],
p = 0.60) and cancer mortality rate (0.99 [0.96, 1.03],
p = 0.69) (Table 2). Diabetes was listed anywhere on the death
certificate for 981 individuals (77 in the screening group
[0.7%] and 904 in the control group [0.6%]). There was no
significant difference between groups in diabetes-related mor-
tality rate (1.10 [0.84, 1.44], p = 0.51; Table 2).
Effect of screening on CVD Median duration of follow-up
was 9.5 years (16,499,722 person-years). Following entry to
the study, there were 17,941 first CVD events in the screening
group (11.7%) and 208,476 in the no-screening group (11.8%)
(HR 0.99 [95% CI 0.96, 1.02], p = 0.49) (Table 2). The
composite CVD event included 12,552 CVD deaths,
138,809 non-fatal IHD and 75,057 non-fatal strokes.
Cardioprotective medication At baseline, the proportion of
participants redeeming cardioprotective medication was simi-
lar in both groups (Table 3). Following commencement of the
screening programme in 2001, larger numbers of people in the
screening practices redeemed glucose-lowering medication
compared with control practices (after excluding individuals
with prevalent diabetes in each practice). This difference
narrowed over time but was maintained until 2007, when both
groups were prescribed similar levels of glucose-lowering
medication (30,824 [1.81%] in the no-screening group and
2769 [1.87%] in the screening group). Similarly, larger num-
bers of people in the screening practices redeemed lipid-
lowering prescriptions compared with the control practices.
Similar proportions of participants in both groups redeemed
Table 2 Incidence of all-cause and cardiovascular-, cancer- and diabetes-related mortality, and CVD events, by screening group (2001–2012)
Variable Screening group (n = 153,107) No-screening group (n = 1,759,285) Adjusted HRa
(95% CI)
Number
of events
Person-years
of follow-up
Rate per 1000
person-years
(95% CI)
Number
of events
Person-years
of follow-up
Rate per 1000
person-years
(95% CI)
Mortality
All-cause 11,826 1,425,981 8.29 (8.15, 8.44) 141,719 15,972,368 8.87 (8.83, 8.92) 0.99 (0.96, 1.02)
Cardiovascular-related 2291 1,425,981 1.61 (1.54, 1.67) 27,435 15,972,368 1.72 (1.70, 1.74) 1.02 (0.96, 1.08)
Cancer-related 5387 1,425,981 3.78 (3.68, 3.88) 62,307 15,972,368 3.90 (3.87, 3.93) 0.99 (0.96, 1.03)
Diabetes-relatedb 74 1,425,981 0.05 (0.04, 0.07) 904 15,972,368 0.06 (0.05, 0.06) 1.10 (0.84, 1.44)
Composite cardiovascular eventc 17,941 1,352,463 13.28 (13.08, 13.47) 208,476 15,148,258 13.76 (13.70, 13.82) 0.99 (0.96, 1.02)
a HRwas estimated with a Cox proportional hazards regression model. Robust SEs were calculated taking into account the two-level structure of the data
and any potential correlation between individuals within practices. Models were adjusted for age, sex, education and prevalent chronic disease (IHD,
stroke, cancer); baseline hazards were stratified by county
bDiabetes-related mortality includes any death with an ICD-10 code E10* to E14*
c First of CVD death, non-fatal IHD or non-fatal stroke
Table 1 Baseline characteristics
of participants in the screening
and no-screening groups (2001–
2006)
Characteristic Screening group
(n = 153,107)
No-screening (control)
group (n = 1,759,285)
Mean age (SD), years 53.6 (8.1) 53.4 (8.2)
Male sex, n (%) 75,569 (49.4) 875,241 (49.8)
Years of education, n (%)a
0–10 46,232 (30.8) 571,727 (33.4)
10–15 69,025 (46.1) 808,851 (47.3)
> 15 34,648 (23.1) 330,096 (19.3)
European citizenship, n (%)a 151,937 (99.3) 1,738,603 (99.0)
Previous IHDb, n (%) 4989 (3.3) 63,734 (3.6)
Previous strokeb, n (%) 2313 (1.5) 29,023 (1.7)
Previous cancerb, n (%) 15,210 (9.9) 179,000 (10.2)
a Totals do not match denominator owing to missing data
b Data taken from the National Patient Registry; data available from 1994 onwards
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prescriptions for anti-hypertensive medication throughout the
follow-up period.
Discussion
In this population-based sample of nearly two million middle-
aged Danish adults, a single round of screening for type 2
diabetes and cardiovascular risk assessment was not associat-
ed with a reduction in the rates of all-cause mortality or car-
diovascular events between 2001 and 2012. Similarly, rates of
cardiovascular-, cancer- and diabetes-related mortality were
not reduced by invitation to screening.
Modelling studies have previously suggested a benefit of
population screening for diabetes and related risk factors for
vascular disease [3–7]. This finding was supported by exam-
ination of the Ely cohort [22], in which individuals aged
40–65 years who were invited to diabetes screening every
5 years between 1990 and 1999 had a non-significant 21%
lower all-cause mortality rate than individuals who were not
invited to screening; however, this finding was not replicated
in between 2000 and 2008.
A more recent screening and health promotion CVD inter-
vention undertaken in Västerbotten County, Sweden, also
showed a significant long-term reduction in all-cause and
CVD mortality rates when compared with the general
Swedish population [11]. This complex intervention was dif-
ferent from the ADDITION-Denmark study. The screening
programme and health counselling offered to individuals
was nested within a public health prevention programme
targeting the wider collective determinants of diabetes and
CVD. However, our findings mirror those of a pragmatic,
parallel-group, cluster-randomised trial in 33 general practices
in eastern England (ADDITION-Cambridge) [8], in which
screening for type 2 diabetes in those at high risk did not result
in a reduction in all-cause or cardiovascular- or diabetes-
related mortality rates over 10 years. Our results also reaffirm
a recent Cochrane review [10], which found no long-term
impact of general health checks on mortality and morbidity
rates following population screening.
There are many potential explanations for the lack of dif-
ference in mortality rates and cardiovascular events observed
in this trial. The study was undertaken against a background of
national interest about screening and early treatment for dia-
betes in Denmark. The effect of screening may therefore have
been diluted by opportunistic screening in primary care and by
continuing improvement in the detection and management of
CVD risk factors. Only 27,177 (18%) of individuals in the
screening group attended their general practice for testing
which combined with the less than 100% sensitivity at each
step of the screening programme might have contributed to
the low yield of individuals found to have detectable disease
(1% of the invited population) [14]. Although earlier detection
may have benefitted those diagnosed with diabetes [18], the
proportion was probably too small to affect population mor-
tality rates. Furthermore, screening attendees are frequently
those at lowest risk [23].
For cancers such as prostate, any effect of screening on
population mortality rates is achieved largely through the effect
of treatment in the lead time between detection by screening
and clinical diagnosis [24]. By contrast, CVD risk factor
screening identifies a significant proportion of the population
that might benefit from health promotion and lifestyle change,
which could also impact other health outcomes such as cancer.
Unlike the ADDITION-Cambridge trial, the Danish screening
programme included assessment of CVD risk factors alongside
screening for undiagnosed prevalent diabetes. This is similar to
recommendations in the UK NHS Health Checks Programme
Table 3 Redeemed cardioprotective medication from 2000 to 2008
Yeara Glucose-lowering medication Lipid-lowering medication Anti-hypertensive medication
Screening No-screening p value Screening No-screening p value Screening No-screening p value
2000 14 (0.01) 215 (0.01) 0.29 3137 (2.1) 36,286 (2.1) 0.72 20,629 (13.5) 241,916 (13.8) 0.0025
2001 83 (0.05) 188 (0.01) <0.0001 3921 (2.56) 45,443 (2.58) 0.63 23,097 (15.09) 268,441 (15.26) 0.086
2002 275 (0.18) 219 (0.01) <0.0001 5402 (3.54) 59,709 (3.39) 0.0030 25,884 (16.95) 298,665 (16.98) 0.79
2003 666 (0.44) 3373 (0.19) <0.0001 7836 (5.15) 82,590 (4.71) <0.0001 29,087 (19.13) 333,731 (19.03) 0.34
2004 1103 (0.73) 9652 (0.55) <0.0001 10,974 (7.26) 114,726 (6.59) <0.0001 32,117 (21.24) 371,711 (21.34) 0.35
2005 1567 (1.04) 15,899 (0.92) <0.0001 13,712 (9.12) 148,728 (8.60) <0.0001 35,286 (23.47) 407,319 (23.55) 0.50
2006 2119 (1.42) 22,810 (1.33) 0.0036 17,116 (11.47) 191,917 (11.18) 0.0010 38,826 (26.01) 446,981 (26.05) 0.74
2007 2769 (1.87) 30,824 (1.81) 0.11 21,029 (14.20) 236,299 (13.89) 0.0011 42,207 (28.49) 485,665 (28.55) 0.66
2008 3490 (2.38) 40,117 (2.38) 0.93 25,034 (17.04) 284,675 (16.88) 0.12 45,454 (30.94) 522,555 (30.99) 0.69
Data are presented as n (%)
ATC codes: glucose-lowering medication (A*); lipid-lowering medication (C10*); anti-hypertensive medication (CO7*, CO8*, C09*)
a Denominator population based on participants who were alive on 1 January for each year
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[1]. Danish GPs were encouraged to intervene in individuals
with IFG/IGT and those with high CVD risk but without diag-
nosed diabetes. While small numbers of individuals were diag-
nosed with diabetes following screening in Denmark (1%),
1.6% were found with IFG/IGT and 48% with elevated cardio-
vascular risk (SCORE > 5 points), providing a larger at-risk
group with the potential to benefit from interventions to prevent
both diabetes and CVD [25, 26]. Indeed, larger proportions of
people in the screening practices redeemed cardioprotective
medication compared with the control practices during the
screening phase of the study (2001–2006). However, these dif-
ferences were small and were not sustained. Furthermore, there
is evidence of sub-optimal treatment among individuals identi-
fied at high risk in health check programmes [27] and among
those with screen-detected diabetes [18], which might have
contributed to the lack of difference between groups. Indeed,
follow-up of ADDITION-Denmark participants who did not
have diabetes but had high CVD risk and dyslipidaemia
showed that only 20% were started on lipid-lowering treatment
following screening [28]. Of these, only 53% reached the treat-
ment goal of total cholesterol <5.0mmol/l and LDL-cholesterol
<3 mmol/l within 1 year of starting treatment [29]. Among
those with screen-detected diabetes, there was wide variation
between general practices in prescription of lipid-lowering
treatment [30]. As such, there is evidence of both under-
treatment and considerable delay in starting treating among this
high-risk population. Benefits to the population might have
been increased by identification of non-attenders, targeting of
screening to those at greatest risk, strategies tomaximise uptake
of screening (particularly among those at highest risk), repeated
rounds of screening and optimal treatment of detected disease.
Benefits might also be increased by introducing complex inter-
ventions that target collective determinants of chronic disease
alongside individualised screening and treatment programmes.
For example, the Västerbotten Intervention Programme aimed
to raise public awareness of CVD risk factors and lifestyle
behaviours by tailoring activities to the local community, in-
cluding the introduction of ‘the green keyhole’ food labelling
system denoting low fat and high fibre foods, development of
healthy school lunches, production and distribution of health
educational materials, and health information meetings [11].
Participation rates in Västerbotten were 48–67%. Our results
underline the continuing uncertainty about the overall benefits
of population screening for diabetes and CVD.
As with all screening programmes, positive health out-
comes are associated with uptake. In common with findings
from other population-based screening programmes, we ob-
served the lowest mortality rates in attenders, probably due, at
least in part, to healthy volunteer bias.
Strengths and limitations This very large non-randomised,
controlled trial with 9.5 years of follow-up included all indi-
viduals aged 40–69 years without diagnosed diabetes in
Denmark between 2001 and 2006. Outcome ascertainment
was robust. The National Death Registry estimates 100% cov-
erage of mortality based on death certificates. All-cause mor-
tality is an all-inclusive measure that addresses both direct and
indirect benefits and harms of screening, and puts disease-
specific mortality rate reduction in the context of other com-
peting risks [12]. We were able to ascertain which individuals
were living in Denmark during the screening period and those
who emigrated during follow-up. Deaths and CVD events
were coded blind to study group. We used a validated risk
score developed and evaluated in a Danish population to iden-
tify those at high risk of undiagnosed diabetes [15].
A limitation of our study includes the post hoc, non-
randomised design, which means that we cannot eliminate
the possibility of selection bias and residual confounding.
Groups were well balanced for most baseline characteristics.
However, there were higher levels of education and slightly
lower levels of pre-existing chronic disease in the screening
compared with the no-screening group. These differences
would have tended to increase the apparent benefits of screen-
ing. In order to minimise the impact of these small baseline
differences between study groups, we adjusted for age, sex,
education and prevalent chronic disease at the individual lev-
el. We also accounted for clustering and stratified the baseline
hazard function by county to allow for potential baseline dif-
ferences in underlying determinants of disease by geographi-
cal region.
In terms of practice characteristics, data were not available
with which to compare the screening and no-screening
groups. The small differences at baseline between study
groups suggest that practices participating in ADDITION-
Demark served less deprived regions than the average
Danish practice. The benefits of screening might be greater
among more socioeconomically deprived communities in
which the absolute disease risk is higher, although attendance
for screening is likely to be lower [23]. The vast majority of
participants were white European, the main ethnic group in
Denmark, which also limits generalisability to other settings.
We did not measure the potential psychological harms of
screening for diabetes and related cardiovascular risk factors
and subsequent treatment in ADDITION-Denmark. However,
previous research suggests that such adverse effects are limit-
ed in both the short and longer term [31, 32].
While we were able to compare trends in redeemed
cardioprotective medication to explore a potential effect of
the screening programme, it would also have been useful to
examine diet, physical activity and smoking behaviour.
However, these data are not available for the entire Danish
population. One-third of the individuals diagnosed with dia-
betes by screening in ADDITION-Denmark reported that they
had stopped smoking by five-year follow-up. Furthermore the
cohort lost an average of 2 kg in weight [18]. These behav-
ioural responses further suggest that detection of diabetes by
Diabetologia
screening was associated with a positive impact among those
found to have undiagnosed prevalent disease. Indeed, the re-
sults of this study must be placed in a wider context about the
benefits of screening for those with detectable disease. There
is growing evidence for the benefit of intensive treatment of
risk factors early in the course of the disease [33]. Results from
ADDITION-Europe, a cluster-randomised trial of intensive,
target-driven management of screen-detected individuals,
showed that those identified and treated earlier had a mortality
rate that was similar to that reported for people of the same age
without diabetes in the general population in Denmark [18].
The possibility also remains that screening for diabetes and
CVD risk factors followed by multifactorial treatment may
have effects on microvascular and other morbidity not evalu-
ated in this study. Furthermore, in a separate paper comparing
the mortality rate and cardiovascular outcomes in individuals
with incident diabetes in the screened group with those from
the unscreened group, we show significant benefits for those
diagnosed with diabetes in the screening practices [34]. Thus,
while screening for diabetes and CVD risk factors may not
have an impact at the population level, it appears to have
benefits for the small subgroup found to have undiagnosed
prevalent diabetes.
In conclusion, invitation to one round of screening for type
2 diabetes and cardiovascular risk assessment among middle-
aged adults in Danish general practice was not associated with
a significant reduction in mortality rate or CVD events be-
tween 2001 and 2012. The benefits of population-based
screening may be lower than expected and limited to individ-
uals with detectable disease.
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